Hartford,CT-based Aetna announced that its board of directors decided to split the company's global health and global financial services into two independent, publicly traded companies.
Hartford,CT-based Aetna announced that its board of directors decided to split the company's global health and global financial services into two independent, publicly traded companies.
"We strongly believe that the interests of our shareholders, employees, customers and the communities in which we operate are well served by this plan and by the additional steps we will be taking to improve our business," said Aetna chairman and CEO William H. Donaldson.
Aetna's other steps include:
•Â The sale of international assets that do not fit with the strategies of the newly independent health and wealth businesses, or provide an adequate return on capital.
•Â Finalizing plans to capture strategic healthcare Internet opportunities that leverage Aetna's healthcare information technology assets.
•Â A comprehensive review of the company's health business model and strategies with the goal of building on the franchise and improving financial performance in addition to relationships with physicians, hospitals and patients.
•Â Additional, undisclosed efforts to strengthen the financial services business and enhance its products and services.
•Â The acceleration of an existing cost-reduction program and additional reductions resulting from the company's restructuring and strategic review.
According to Donaldson, the plan came in part from a desire to better accommodate the changing managed care environment. "In health, we will examine our business model in view of a rapidly changing environment that increasingly emphasizes choice and empowerment," said Donaldson. "Our goal is to improve relations with physicians and hospitals, do a better job of meeting the expectations of customers and patients and enhance our financial performance."
Decisions have yet to be made on company names, headquarter locations, corporate staffs and boards of directors for the two companies. The move is also subject to obtaining regulatory approvals and satisfaction of certain legal requirements. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.